All In Biotech

Drug Trial Radar · NCT04709094

A Drug Interaction Study of Danicopan

A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Warfarin, Bupropion, and Ethinyl Estradiol and Norethindrone (Oral Contraceptive) in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Jan 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jul 28, 2019

Primary completion

Oct 14, 2019

Study completion Apr 17, 2020

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Achillion, a wholly owned subsidiary of Alexion; Celerion
First posted
Jan 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a 3-part study (Part 1, Part 2, Part 3) with each part being an open-label, fixed sequence, 2-period study in healthy adult participants.

Conditions

  • Healthy

Interventions

  • DanicopanDrug

    Danicopan was dosed as 2 x 100 milligram (mg) tablets.

  • WarfarinDrug

    Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).

  • BupropionDrug

    Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.

  • Ethinyl Estradiol/NorethindroneDrug

    EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Warfarin Under Multiple Doses Of DanicopanTime frame: Up to 168 hours postdose
  2. Part 1: Maximum Observed Concentration (Cmax) Of Single-dose Warfarin Under Multiple Doses Of DanicopanTime frame: Up to 168 hours postdose
  3. Part 1: Time To Maximum Observed Concentration (Tmax) Of Single-dose Warfarin Under Multiple Doses Of DanicopanTime frame: Up to 168 hours postdose
  4. Part 2: AUC0-inf Of Single-dose Bupropion Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
  5. Part 2: Cmax Of Single-dose Bupropion Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
  6. Part 2: Tmax Of Single-dose Bupropion Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
  7. Part 3: AUC0-inf Of Single-dose EE/NET Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
  8. Part 3: Cmax Of Single-dose EE/NET Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose
  9. Part 3: Tmax Of Single-dose EE/NET Under Multiple Doses Of DanicopanTime frame: Up to 96 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Study Site

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.